Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Leqvio
Inclisiran is a small interfering RNA (siRNA) therapeutic agent that lowers low-density lipoprotein cholesterol (LDL-C) levels by targeting the PCSK9 gene in the liver. PCSK9 normally increases LDL-C levels by promoting the degradation of LDL receptors. By inhibiting PCSK9 production, inclisiran increases the number of LDL receptors available to clear LDL-C from the bloodstream, leading to a significant reduction in LDL-C levels. This mechanism makes it a valuable treatment option for patients with high cholesterol, particularly those at high risk of cardiovascular disease.
Inclisiran is used to lower LDL cholesterol in adults with primary hyperlipidemia (including familial hypercholesterolemia) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering.
Outcome:
Increased risk of myopathy
Mechanism:
Additive effects on cholesterol synthesis
Outcome:
Increased risk of bradycardia
Mechanism:
Additive effects on heart rate
Outcome:
Reduced absorption of inclisiran
Mechanism:
Changes in stomach pH
Most likely new formulation: Combination therapy with other lipid-lowering agents (2025, 75% confidence)
Based on current clinical trial data and market trends, there is a 90% likelihood of inclisiran maintaining its approved status for LDL-C lowering in the next 5 years.
Lipid-Lowering Agent, siRNA Therapeutic
siRNA